当前位置： SCI文献检索 > CLINICAL AND EXPERIMENTAL IMMUNOLOGY期刊下所有文献 > Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.

Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.

Abstract：

:Complement receptor 1-related gene/protein y (Crry) is a potent murine complement regulator that inhibits C3 convertases. Transgenic mice that overexpress soluble Crry (sCrry), directed systemically by the metallothionein-I promoter, have been used as an animal model for chronic blockade of complement activation. Recently we have found that alternative pathway (AP) activity in Crry transgenic mice was not inhibited as much as expected. To elucidate the mechanism of this effect, we evaluated the AP activities and levels of sCrry and AP complement components in transgenic and non-transgenic mice. In transgenic mice, expression of sCrry was induced by feeding zinc sulphate solution to 70.1 +/- 42.7 micro g/ml mean serum level. Its corresponding level of purified sCrry inhibited 49% of AP activity of normal mice serum; however, the actual AP activities in transgenic mice were not decreased when compared to non-transgenic mice (130.2 +/- 9.0%versus 113.0 +/- 35.4%). Expressed sCrry was functional, as immunoprecipitation and removal of sCrry from transgenic sera with rabbit anti-Crry polyclonal antibody resulted in enhanced AP activity, consistent with initial levels of sCrry. We then compared the changes to C3, factor B, factor H and factor D serum levels in transgenic and non-transgenic mice after induction of sCrry expression. Of these only C3 was increased after zinc feeding in transgenic mice compared to non-transgenic mice (142.8 +/- 14.1%versus 121.4 +/- 15.1%, P = 0.023). These results suggest that the inhibitory effect of chronic exposure to sCrry is compensated by concomitant alteration in C3 levels. This result also suggests the presence of a complement regulatory protein controls the level of serum C3, which has potential importance in the design and interpretation of studies involving chronic use of complement inhibitors.

journal_name

Clin Exp Immunol

journal_title

Clinical and experimental immunology

authors

Kang HJ,Bao L,Xu Y,Quigg RJ,Giclas PC,Holers VM

doi

10.1111/j.1365-2249.2004.02450.x

subject

Has Abstract

pub_date

2004-05-01 00:00:00

pages

194-9

issue

eissn

0009-9104

issn

1365-2249

pii

CEI2450

journal_volume

136

pub_type

杂志文章

在线工具

Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.